Quality specifications for B-type natriuretic peptide assays

Fred S. Apple, Mauro Panteghini, Jan Ravkilde, Johannes Mair, Alan H.B. Wu, Jillian Tate, Franca Pagani, Robert H. Christenson, Allan S. Jaffe

Research output: Contribution to journalArticlepeer-review

156 Scopus citations


Background: The objective of this report is to improve the quality of immunochemical measurements of B-type natriuretic peptide (BNP) and its N-terminal propeptide (NT-proBNP). The recommendations proposed are intended for use by manufacturers of commercial assays, by clinical laboratories using those assays, by clinical trial groups and research investigators, and by regulatory agencies, such as the United States Food and Drug Administration. Methods: A group of cardiac biomarker experts reviewed and abstracted the scientific literature to provide recommendations pertaining to the quality specifications for BNP/NT-proBNP assays. Results: The evidence-based recommendations encourage manufacturers to endorse and consistently follow the proposed recommendations; encourage that all package inserts for BNP/NT-proBNP immunoassays include uniform information on assay design, preanalytical performance characteristics, analytical performance characteristics, and clinical performance; and encourage regulatory agencies to adopt a minimal and uniform set of criteria for manufacturers to provide when seeking clearance for new and/or improved assays. Conclusions: These recommendations address the use of BNP and NT-proBNP as cardiac biomarkers and not their physiologic and/or pathophysiologic relevance.

Original languageEnglish (US)
Pages (from-to)486-493
Number of pages8
JournalClinical chemistry
Issue number3
StatePublished - Mar 2005

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Quality specifications for B-type natriuretic peptide assays'. Together they form a unique fingerprint.

Cite this